Study identifies new marker to find patients with advanced prostate cancer more likely to benefit from combination immunotherapy
Peer-Reviewed Publication
Updates every hour. Last Updated: 22-Jun-2026 10:16 ET (22-Jun-2026 14:16 GMT/UTC)
Researchers with the James P. Allison Institute™ at The University of Texas MD Anderson Cancer Center have discovered a new gene expression signature within tumors that can help identify patients with metastatic castration-resistant prostate cancer (mCRPC) who are more likely to experience lasting benefits from combined immunotherapy treatment.
Mass General Brigham study of more than 6,000 patients highlights the need for long-term personalized surveillance strategies
First major U.S. rollout of HPV self-collection shows benefits for patients and providers, including fewer pelvic exams and better follow-up for HPV-positive results